Synergistic Effects of Zinc Oxide Nanoparticles and Various Antibiotics Combination Against Clinically Isolated Bacterial Strains

Overview

Journal Saudi J Biol Sci

Specialty Biology

Date 2021 Jan 11

PMID 33424384

Citations 18

Authors

Alshareef O Fadwa

Dena K Alkoblan

Ayesha Mateen

Ahmed M Albarag

Affiliations

Soon will be listed here.

Abstract

causes mostly both community-acquired and nosocomial infections, which leads to serious therapeutic challenges for treatment and requirement of appropriate therapeutic agent is needed which can combat antibiotic resistance. The research work was performed to investigate the effect of Zinc Oxide nanoparticles (ZnO NPs) in combination with Meropenem, Ciprofloxacin, and Colistin against clinical isolated strains of and ATCC 27853 strain. The minimum inhibitory concentration (MIC) of ZnO NPs and the antibiotics (Meropenem, Ciprofloxacin, and Colistin), was determined by the microdilution method and the results of MIC values were ranging between 1 and 16 µg/mL was found to be shown for antibiotics and ZnO NPs found to showed highest MIC values ranging from 2000 to 4000 µg/mL. The fractional inhibitory concentration index (FICI) was calculated using checkerboard method to test the combinations of ZnO NPs and the antibiotics (Meropenem, Ciprofloxacin, and Colistin), and among all the six clinical isolated strains (MRO-16-3 and MRO-16-4), showed FICI as 0.24 and 0.39 9, whereas ATCC 27853 strain showed FICI as 0.41 which indicates synergistic effect with Colistin. The time kill growth curve showed synergistic effect for the combination of Colistin and ZnO NPs against (MRO-16-3 and MRO-16-) strains. (MRO-16-3) was found to be highly sensitive to Colistin with an MIC of 2 µg/mL, which has shown to reduced bacterial growth to zero colonies after 24 h of incubation. In conclusion, combination of Colistin and ZnO NPs at appropriate dosage intervals might be beneficial as using therapeutic agent in treatment of ailments.

Citing Articles

Hexagonal zinc oxide nanoparticles: a novel approach to combat multidrug-resistant biofilms in feline urinary tract infections.

Sewid A, Sharaf M, El-Demerdash A, Ragab S, Al-Otibi F, Taha Yassin M Front Cell Infect Microbiol. 2025; 14:1505469.

PMID: 39926113 PMC: 11802582. DOI: 10.3389/fcimb.2024.1505469.

Green Synthesis of Zinc Oxide Nanoparticles: Preparation, Characterization, and Biomedical Applications - A Review.

El-Saadony M, Fang G, Yan S, Sami Alkafaas S, El Nasharty M, Khedr S Int J Nanomedicine. 2024; 19:12889-12937.

PMID: 39651353 PMC: 11624689. DOI: 10.2147/IJN.S487188.

Recent Advances in the Development of Metal/Metal Oxide Nanoparticle and Antibiotic Conjugates (MNP-Antibiotics) to Address Antibiotic Resistance: Review and Perspective.

Abdullah , Jamil T, Atif M, Khalid S, Metwally K, Yahya G Int J Mol Sci. 2024; 25(16).

PMID: 39201601 PMC: 11354832. DOI: 10.3390/ijms25168915.

ZnO nanoparticles induced biofilm formation in Klebsiella pneumoniae and Staphylococcus aureus at sub-inhibitory concentrations.

K S, Nechikkadan S, Theresa M, Krishnankutty R Folia Microbiol (Praha). 2024; 69(6):1175-1183.

PMID: 38564153 DOI: 10.1007/s12223-024-01158-z.

Poly-Gamma-Glutamic Acid Nanopolymer Effect against Bacterial Biofilms: In Vitro and In Vivo Study.

Elsayed E, Farghali A, Zanaty M, Abdel-Fattah M, Alkhalifah D, Hozzein W Biomedicines. 2024; 12(2).

PMID: 38397853 PMC: 10887140. DOI: 10.3390/biomedicines12020251.

References

Ghasemi F, Jalal R . Antimicrobial action of zinc oxide nanoparticles in combination with ciprofloxacin and ceftazidime against multidrug-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2016; 6:118-122. DOI: 10.1016/j.jgar.2016.04.007. View

Xie Y, He Y, Irwin P, Jin T, Shi X . Antibacterial activity and mechanism of action of zinc oxide nanoparticles against Campylobacter jejuni. Appl Environ Microbiol. 2011; 77(7):2325-31. PMC: 3067441. DOI: 10.1128/AEM.02149-10. View

Drenkard E . Antimicrobial resistance of Pseudomonas aeruginosa biofilms. Microbes Infect. 2003; 5(13):1213-9. DOI: 10.1016/j.micinf.2003.08.009. View

Mulcahy L, Burns J, Lory S, Lewis K . Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol. 2010; 192(23):6191-9. PMC: 2981199. DOI: 10.1128/JB.01651-09. View

Bisbe J, Gatell J, Puig J, Mallolas J, Martinez J, Jimenez de Anta M . Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis. 1988; 10(3):629-35. DOI: 10.1093/clinids/10.3.629. View

Li J, Milne R, Nation R, Turnidge J, Coulthard K, Valentine J . Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother. 2002; 46(10):3304-7. PMC: 128774. DOI: 10.1128/AAC.46.10.3304-3307.2002. View

Gordon N, Png K, Wareham D . Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010; 54(12):5316-22. PMC: 2981237. DOI: 10.1128/AAC.00922-10. View

Wright G . Bacterial resistance to antibiotics: enzymatic degradation and modification. Adv Drug Deliv Rev. 2005; 57(10):1451-70. DOI: 10.1016/j.addr.2005.04.002. View

Gupta S, Govil D, Kakar P, Prakash O, Arora D, Das S . Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med. 2009; 13(2):49-53. PMC: 2772240. DOI: 10.4103/0972-5229.56048. View

10.

Vidaillac C, Benichou L, Duval R . In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012; 56(9):4856-61. PMC: 3421898. DOI: 10.1128/AAC.05996-11. View

11.

Dupuy F, Pagano I, Andenoro K, Peralta M, Elhady Y, Heinrich F . Selective Interaction of Colistin with Lipid Model Membranes. Biophys J. 2018; 114(4):919-928. PMC: 5985005. DOI: 10.1016/j.bpj.2017.12.027. View

12.

Balaji V, Jeremiah S, Baliga P . Polymyxins: Antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol. 2011; 29(3):230-42. DOI: 10.4103/0255-0857.83905. View

13.

Rikans L, Hornbrook K . Lipid peroxidation, antioxidant protection and aging. Biochim Biophys Acta. 1998; 1362(2-3):116-27. DOI: 10.1016/s0925-4439(97)00067-7. View

14.

Kelly K, Havrilla C, Brady T, Abramo K, Levin E . Oxidative stress in toxicology: established mammalian and emerging piscine model systems. Environ Health Perspect. 1998; 106(7):375-84. PMC: 1533135. DOI: 10.1289/ehp.98106375. View

15.

Malekzadegan Y, Abdi A, Heidari H, Moradi M, Rastegar E, Ebrahim-Saraie H . In vitro activities of colistin, imipenem and ceftazidime against drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii isolates in the south of Iran. BMC Res Notes. 2019; 12(1):301. PMC: 6540545. DOI: 10.1186/s13104-019-4344-7. View

16.

Breidenstein E, de la Fuente-Nunez C, Hancock R . Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011; 19(8):419-26. DOI: 10.1016/j.tim.2011.04.005. View

17.

Wiseman L, Wagstaff A, Brogden R, Bryson H . Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995; 50(1):73-101. DOI: 10.2165/00003495-199550010-00007. View

18.

Shopsin B, Gomez M, Montgomery S, Smith D, Waddington M, Dodge D . Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol. 1999; 37(11):3556-63. PMC: 85690. DOI: 10.1128/JCM.37.11.3556-3563.1999. View

19.

Micek S, Lloyd A, Ritchie D, Reichley R, Fraser V, Kollef M . Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005; 49(4):1306-11. PMC: 1068618. DOI: 10.1128/AAC.49.4.1306-1311.2005. View

20.

Bayroodi E, Jalal R . Modulation of antibiotic resistance in Pseudomonas aeruginosa by ZnO nanoparticles. Iran J Microbiol. 2016; 8(2):85-92. PMC: 4906724. View